Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

SAB Biotherapeutics, Inc. SABS

Healthcare  —  Biotechnology
3.29 (0.06) (1.79%) as of 25 Sep
Market cap
$304.8M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

SAB Biotherapeutics, Inc. (SABS) Business Profile

Updated before January 2025

Company Overview

SAB Biotherapeutics, Inc. (SABS) is a clinical-stage biopharmaceutical company that specializes in developing and commercializing immunotherapeutic solutions. Founded in 2014 and headquartered in Sioux Falls, South Dakota, SABS was established with the mission of leveraging advanced biotechnology to address unmet medical needs in infectious diseases, immune system disorders, and other critical health challenges. The company was co-founded by Dr. Eddie Sullivan, who serves as the President and CEO, and has been instrumental in steering the company’s innovative research and development efforts. SABS is recognized for its proprietary DiversitAb™ platform, which enables the rapid development of targeted, fully human polyclonal antibodies.

The leadership team at SABS includes seasoned professionals with extensive experience in biotechnology, pharmaceuticals, and healthcare innovation. Dr. Eddie Sullivan, a pioneer in the field of transgenic biotechnology, leads the company alongside a team of experts in immunology, clinical development, and regulatory affairs. Together, they have positioned SABS as a leader in the development of next-generation immunotherapies.

Core Business Segments

SAB Biotherapeutics operates primarily in the field of immunotherapy, with a focus on developing fully human polyclonal antibody therapies. The company’s core business segments include:

Infectious Diseases

SABS develops therapies to combat infectious diseases, including viral and bacterial infections. Its flagship product, SAB-185, is a fully human polyclonal antibody therapeutic designed to treat COVID-19. SAB-185 has shown promise in clinical trials and is being developed as a potential treatment for severe cases of the disease.

Immune System Disorders

The company is also focused on addressing immune system disorders, such as autoimmune diseases and allergic conditions. By leveraging its DiversitAb™ platform, SABS is developing therapies that can modulate the immune system and provide relief to patients suffering from chronic conditions.

Oncology

SABS is exploring the application of its technology in oncology, aiming to develop immunotherapies that can enhance the body’s natural ability to fight cancer. This segment is still in the early stages of development but represents a significant growth opportunity for the company.

Biodefense

In collaboration with government agencies and other partners, SABS is working on developing countermeasures for bioterrorism and emerging infectious diseases. This includes the production of antibodies for rare and high-risk pathogens.

Business Model

SAB Biotherapeutics operates on a business model that integrates cutting-edge biotechnology with strategic partnerships to develop and commercialize its products. The company generates revenue through:

  • Collaborations and Partnerships: SABS partners with government agencies, pharmaceutical companies, and research institutions to fund its research and development efforts. For example, the company has received funding from the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA).
  • Product Sales: Once its therapies receive regulatory approval, SABS plans to generate revenue through the sale of its products to healthcare providers and government agencies.
  • Licensing Agreements: The company may also license its DiversitAb™ platform to other biopharmaceutical companies, creating an additional revenue stream.

Strategic Direction

SABS is focused on expanding its pipeline of immunotherapeutic products and advancing its existing candidates through clinical trials. Key strategic priorities include:

  • Pipeline Expansion: The company aims to develop new therapies for a broader range of diseases, including rare and orphan conditions.
  • Global Market Penetration: SABS plans to expand its presence in international markets by forming strategic partnerships and pursuing regulatory approvals in key regions.
  • Sustainability Goals: The company is committed to sustainable manufacturing practices and aims to minimize its environmental footprint by adopting eco-friendly technologies.
  • Innovation in Oncology: SABS is investing in research to explore the potential of its DiversitAb™ platform in oncology, with the goal of developing novel cancer immunotherapies.

Competitive Landscape

SAB Biotherapeutics operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Regeneron Pharmaceuticals: Known for its monoclonal antibody therapies, Regeneron is a major player in the immunotherapy space.
  • Eli Lilly and Company: Eli Lilly has developed antibody-based treatments for COVID-19 and other diseases, making it a direct competitor to SABS.
  • Vir Biotechnology: Specializing in infectious disease treatments, Vir Biotechnology competes with SABS in the development of COVID-19 therapies.
  • Emergent BioSolutions: A leader in biodefense and infectious disease countermeasures, Emergent BioSolutions is another competitor in the field.

Risk Factors

SABS faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The biopharmaceutical industry is heavily regulated, and delays in obtaining regulatory approvals could hinder the company’s ability to commercialize its products.
  • Market Dependence: SABS is reliant on the success of its lead product candidates, such as SAB-185, which increases its exposure to market risks.
  • Supply Chain Disruptions: The company’s manufacturing processes depend on a reliable supply chain, and disruptions could delay production and delivery.
  • Competition: Intense competition from established players in the biopharmaceutical industry poses a significant challenge.
  • Funding Risks: As a clinical-stage company, SABS relies on external funding to support its operations. Any reduction in funding could impact its ability to advance its pipeline.

Recent Developments

SABS has made significant progress in recent years, including:

  • Advancement of SAB-185: The company has completed Phase 2 clinical trials for SAB-185, demonstrating its potential as a treatment for COVID-19. SABS is now preparing for Phase 3 trials.
  • Partnerships: SABS has secured partnerships with government agencies, including BARDA and the Department of Defense, to support the development of its therapies.
  • Technological Innovations: The company continues to enhance its DiversitAb™ platform, enabling the rapid development of new antibody therapies.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of immunotherapies, creating new opportunities for SABS to address global health challenges.

Investment Considerations

Investors considering SABS should weigh the following factors:

Strengths

  • Innovative Technology: The DiversitAb™ platform provides a competitive edge in the development of fully human polyclonal antibodies.
  • Strong Partnerships: Collaborations with government agencies and pharmaceutical companies provide financial support and validation of the company’s technology.
  • Growing Market: The global demand for immunotherapies is increasing, creating significant growth opportunities for SABS.

Risks

  • Clinical and Regulatory Risks: The success of SABS depends on the approval of its product candidates, which are subject to rigorous clinical and regulatory processes.
  • Financial Dependence: As a clinical-stage company, SABS relies on external funding and may face financial challenges if funding sources diminish.
  • Market Competition: The biopharmaceutical industry is highly competitive, and SABS faces competition from established players with greater resources.

Conclusion

SAB Biotherapeutics, Inc. is a pioneering biopharmaceutical company with a strong focus on developing innovative immunotherapies. Leveraging its proprietary DiversitAb™ platform, the company is well-positioned to address unmet medical needs in infectious diseases, immune system disorders, and oncology. While SABS faces challenges such as regulatory hurdles and market competition, its strong partnerships and innovative technology provide a solid foundation for future growth. As the global demand for immunotherapies continues to rise, SABS is poised to play a significant role in shaping the future of healthcare.